Needle Syringes Articles & Analysis
12 news found
” The work was supported through BARDA’s Beyond the Needle program, managed by BARDA DRIVe. This initiative seeks to make vaccines and therapeutics more usable and available by minimizing the reliance on needles, syringes, vials, and cold-chain distribution for the delivery of medical countermeasures. ...
The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a possible alternative to traditional vaccine delivery methods which haven’t seen new technology beyond needle and syringe in over 170 years. In a matter of seconds, the HD-MAP delivers a small volume of vaccine just under the surface of skin where high amounts of immune cells ...
Portal develops technology which allows for needle-free and high-speed subcutaneous injection of medicine and – via connectivity –adherence monitoring along the treatment journey by patient and medical care provider. ...
The proprietary consumables include two different multi-needle heads, syringe cartridges, and liners. High-value market applications for the device include the injection of various substances into the dermal and subcutaneous layers. ...
The patient still has to visit a center, the administration still has to be done by a healthcare professional and the needle still has to be inserted over 5 minutes under the skin of the patient. ...
But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation. ...
Signed in May 2020, the acquistion brings the assets and international business of the ClickZip® Needle Retractable Safety Syringe into Numedico’s expanding portfolio of safe medical devices and will enable a cohesive expansion of the ClickZip® range of retractable needle safety syringes through Asia, EU, USA and ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. ...
Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and potential dose-wasting issues linked to the type of ...
Micron’s applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income countries as it is designed to offer the following benefits and advantages over vaccination by standard hypodermic needle and syringe: strong immune response due to vaccine delivery to the skin, ...
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/sharpsinc/48184/ Since inception of the Company, Sharps Compliance's customers have prevented improper disposal of more than 600 million syringes from the solid waste stream and from potentially harming our citizens and the environment. ...